Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure

Tumor Biology

Volumn 32, Issue 2, 2011, Pages 399-408

  Sagawa, Yasukazu ^a   Fujitoh, Atsuya ^a   Nishi, Hirotaka ^a   Ito, Hiroe ^a   Yudate, Tamaki ^a   Isaka, Keiichi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin (CDDP); Endometrial cancer; Multidrug resistance

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 1BETA CONVERTING ENZYME; LACTATE DEHYDROGENASE; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; SIALYL LEWIS X ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL INVASION; CELL ISOLATION; CELL LEVEL; CELL PROLIFERATION; CELL SIZE; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; EICR IA CELL LINE; EICR IF CELL LINE; EICR II CELL LINE; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; CANCER INVASION; DOSE RESPONSE; DRUG RESISTANCE; ENDOMETRIUM TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MITOMYCIN; NEOPLASM INVASIVENESS; PLATINUM;

EID: 79953771712     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0133-6     Document Type: Article

References (31)

1. Tominaga S et al. Cancer mortality and morbidity statistics. Tokyo: Japan Scientific Societies; 1994.
2. Rosenberg B, VanCamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698-9.
3. Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21:107-13. (Pubitemid 24060847)
4. Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD. Phase II trial of cisplatin as secondline chemotherapy in patients with advanced or recurrent endometrial carcinoma. A gynecologic oncology group study. Am J Clin Oncol. 1984;7:253-6. (Pubitemid 14112252)
5. Deppe G, Cohen CJ, Bruckner HW. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. Gynecol Oncol. 1980;10:51-4. (Pubitemid 10048354)
6. Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol. 1982;59:225-8. (Pubitemid 12163082)
7. Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ, et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol. 1991;40:264-7.
8. Barrete RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. Am J Clin Oncol. 1993;16:494-6.
9. Belliveau JF, Posner MR, Ferrari L, Crabtree GW, Cummings FJ, Wiemann MC, et al. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treat Rep. 1986;70:1215-7. (Pubitemid 16004237)
10. Yudate T, Isaka K, Okabe K, Takayama M. Establishment and characterization of the new cell line (EI) from a human endometrial adenocarcinoma. (in Japanese with English abstract) HUMAN CELL. 1995;8(1):43-7.
11. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinease hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-62.
12. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. J Biol Chem. 1987;262:505-8.
13. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004-8.
14. Gottesman MM, Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 1988;263:12163-6.
15. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1998;948:87-128.
16. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst. 1989;81:116-24. (Pubitemid 19031328)
17. Cole SP, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650-4. (Pubitemid 23012438)
18. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance protein, MRP. Eur J Cancer. 1996;32:945-57.
19. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992;89:3070-4.
20. Lai GM, Moscow JA, Alvarez MJ, Fojo AT, Bates SE. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer. 1991;49:688-95.
21. Xu BH, Gupta V, Singh SH. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. Arch Biochem Biophys. 1994;308:164-70. (Pubitemid 24172618)
22. Sriram R, Ali-Osman F, Livingston R, et al. Modulation of topoisomerase (Topo) II on the kinetics of formation and repair of cis-platinum (cis-DDP) in human tumor cells sensitive and resistant to cis-DDP. Proc Am Assoc Cancer Res. 1990;31:335.
23. Dejong S, Zijlstra JG, Mulder MH, Devries EG. Lack of cross-resistance to fustriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol. 1991;28:461-4.
24. Waud WR, Harrison SDJ, Gilbert KS, Laster Jr WR, Griswold Jr DP. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol. 1991;27:456-63.
25. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem. 1983;258:15365-70.
26. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845-53. (Pubitemid 27132097)
27. Glinsky GV, Glinsky VV, Ivanova AB, Hueser CJ. Apoptosis and metastasis: increased resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett. 1997;115:185-93. (Pubitemid 27196604)
28. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell. 1994;79:189-92. (Pubitemid 24324909)
29. Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nat Genet. 1997;16:358-63. (Pubitemid 27323300)
30. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes. Nature. 1992;356:768-74.
31. Lowe SW, Bodis S, MaClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-10. (Pubitemid 24359290)